Private equity investment firms are setting their sights on orthopaedic care as federal regulators and the industry at large look to move more of these treatments away from hospitals and into outpatient settings.
Healthcare experts are predicting a surge of private equity deals in practices that perform hip and knee replacements in the coming months as transactions are finalized.
"We're right on the precipice of seeing a big wave of these deals," Michael Cole, Managing Director and Healthcare Industry Leader at Alvarez & Marsal’s Transaction Advisory Group, told Healthcare Dive. He said his group is working on four deals right now.
Read more of Mike’s insights in the full article in Healthcare Dive here.
Better Data, Better Exits: The New Playbook for Wealth and Insurance Platform Roll-Ups
August 5, 2026
There’s a new value creation imperative for private equity (PE) firms and corporates seeking to roll up financial technology (FinTech) and data platform acquisitions, especially in the extended higher interest rate environment. Many of the traditional value enhancement strategies still matter, but operational platforming—integrating tech, data, and systems—can be a defining competitive advantage in roll-ups.
Alvarez & Marsal's Global Transaction Advisory Group Continues Building in Germany as EMEA Market Demand Strengthens
July 29, 2026
Alvarez & Marsal (A&M), a leading global professional services firm, today announced the appointment of Silvio Ritz as a Managing Director within its Global Transaction Advisory Group (Global TAG).
Managing COVID Vintage Assets
July 27, 2026
During the COVID-19 pandemic, businesses and private equity (PE) funds acquired technology assets at record-high prices. Corporations also took advantage of the favorable market conditions to add software and technology assets to their portfolios.
Conversations with Anthony Caporrino: From Diligence to Value: The New CDD Playbook
July 14, 2026
Alvarez & Marsal Commercial Due Diligence Managing Directors Jennifer Holland and Elizabeth Pearsons share what rigorous commercial diligence looks like in practice, and where most PE firms are getting it wrong.
